Zeist, Netherlands

Riemke Van Dijkhuizen Radersma

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 7.4

ph-index = 2

Forward Citations = 23(Granted Patents)


Location History:

  • Zeist, NL (2019 - 2020)
  • Utrecht, NL (2020)

Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Riemke Van Dijkhuizen Radersma: Innovator in Cancer Treatment

Introduction

Riemke Van Dijkhuizen Radersma is a notable inventor based in Zeist, Netherlands. He has made significant contributions to the field of cancer treatment through his innovative work in antibody development. With a total of five patents to his name, he is recognized for his advancements in targeted therapies.

Latest Patents

Riemke's latest patents include groundbreaking inventions such as anti-AXL antibodies. This invention relates to antibodies that bind to AXL, along with immunoconjugates, compositions, and methods for treating cancer using these antibodies. Another significant patent involves bispecific antibodies against CD3 and CD20. These bispecific antibodies are designed for specific targeting and T cell-mediated killing of cells that express CD20, which is crucial in treating certain diseases.

Career Highlights

Riemke is currently associated with Genmab AS, a leading biotechnology company focused on developing differentiated antibody therapeutics for the treatment of cancer. His work at Genmab has positioned him as a key player in the advancement of innovative cancer therapies.

Collaborations

Riemke collaborates with talented professionals in his field, including Esther Breij and David Satijn. Their combined expertise contributes to the success of their projects and the development of new therapeutic solutions.

Conclusion

Riemke Van Dijkhuizen Radersma is a prominent inventor whose work in antibody development is paving the way for innovative cancer treatments. His contributions are vital in the ongoing fight against cancer, showcasing the importance of research and innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…